0
0

Chapter 55. Treatment of Schizophrenia

Tsung-Ung W. Woo, M.D., Ph.D.; Carla M. Canuso, M.D.; Joanne D. Wojcik, P.M.H.C.N.S.–B.C.; Mary F. Brunette, M.D.; Alan I. Green, M.D.
DOI: 10.1176/appi.books.9781585623860.423569

Sections

Excerpt

Schizophrenia is a debilitating brain disorder characterized by a chronic relapsing and remitting course of psychosis that is superimposed on persistent "deficit" features such as cognitive dysfunction and negative symptoms. It appears to be equally prevalent across geographical and cultural boundaries (see Jablensky et al. 1992), afflicting approximately 1% of the population (Perala et al. 2007).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

References

Abi-Saab WM, D'Souza C, Madonick S, et al: Targeting the glutamate system, in Current Issues in the Psychopharmacology of Schizophrenia. Edited by Breier A, Tran PV, Herrea JM, et al. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 304–332
 
Abraham G, Friedman RH, Verghese C: Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry 40:430–431, 1996
[PubMed]
 
Addington J: Early intervention strategies for co-morbid cannabis use and psychosis. Presented at the Inaugural International Cannabis and Psychosis Conference, Melbourne, Australia, February 16–19, 1999
 
Adler CM, Goldberg TE, Malhotra AK, et al: Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43:811–816, 1998
[PubMed]
 
Albanese MJ: Risperidone in substance abusers with bipolar disorder. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 2000
 
Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696, 1999
[PubMed]
 
Amador XF, Friedman JH, Kasapis C, et al: Suicidal behavior in schizophrenia and its relationship to awareness of illness. Am J Psychiatry 153:1185–1188, 1996
[PubMed]
 
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267–272, 2004
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
 
Ananth J, Vandewater S, Kamal M, et al: Missed diagnosis of substance abuse in psychiatric patients. Hosp Community Psychiatry 40:297–299, 1989
[PubMed]
 
Ananth J, Parameswaran S, Gunatilake S, et al: Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464–470, 2004
[PubMed]
 
Andreasen NC: Positive vs. negative schizophrenia: a critical evaluation. Schizophr Bull 11:380–389, 1985
[PubMed]
 
Andreasen NC, Carpenter WT Jr, Kane JM, et al: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449, 2005
[PubMed]
 
Angermeyer MC, Kuhn L, Goldstein JM: Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull 16:293–307, 1990
[PubMed]
 
Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 175:1054–1060, 1961
[PubMed]
 
Aylward E, Walker E, Bettes B: Intelligence in schizophrenia: meta-analysis of the research. Schizophr Bull 10:430–459, 1984
[PubMed]
 
Baddeley AD: Working Memory. Oxford, UK, Oxford University Press, 1986
 
Baker RW, Chengappa KN, Baird JW, et al: Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 53:439–442, 1992
[PubMed]
 
Baker RW, Ames D, Umbricht DS, et al: Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull 32:89–93, 1996
[PubMed]
 
Banov MD, Zarate CA Jr, Tohen M, et al: Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 55:295–300, 1994
[PubMed]
 
Baptista T: Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 100:3–16, 1999
[PubMed]
 
Barnes TRE, Spence SA: Movement disorders associated with antipsychotic drugs: clinical and biological implications, in Psychopharmacology of Schizophrenia. Edited by Reverly MA, Deakin JFW. New York, Oxford University Press, 2000, pp 178–210
 
Bartels SJ, Drake RE: Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry 29:467–483, 1988
[PubMed]
 
Baxter D, Appleby L: Case register study of suicide risk in mental disorders. Br J Psychiatry 175:322–326, 1999
[PubMed]
 
Beasley CM Jr, Sutton VK, Hamilton SH, et al: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23:582–594, 2003
[PubMed]
 
Bellack AS: Skills training for people with severe mental illness. Psychiatr Rehabil J 27:375–391, 2004
[PubMed]
 
Bellack AS, DiClemente CC: Treating substance abuse among patients with schizophrenia. Psychiatr Serv 50:75–80, 1999
[PubMed]
 
Bellack AS, Mueser KT: Psychosocial treatment for schizophrenia. Schizophr Bull 19:317–336, 1993
[PubMed]
 
Bellack AS, Bennett ME, Gearon JS, et al: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 63:426–432, 2006
[PubMed]
 
Berardi D, Dell'Atti M, Amore M, et al: Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol 17:99–102, 2002
[PubMed]
 
Beresford TP, Clapp L, Martin B, et al: Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 25:363–366, 2005
[PubMed]
 
Bergemann N, Mundt C, Parzer P, et al: Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 73:357–366, 2005
[PubMed]
 
Berman I, Kalinowski A, Berman SM, et al: Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry 36:6–10, 1995a
 
Berman I, Sapers BL, Chang HH, et al: Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol 15:206–210, 1995b
 
Berman KF, Weinberger DR: Neuroimaging studies of schizophrenia, in Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York, Oxford University Press, 1999, pp 246–257
 
Bernardo M, Ramon Azanza J, Rubio-Terres C, et al: Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. Clin Drug Investig 26:447–457, 2006
[PubMed]
 
Bertolino A, Roffman JL, Lipska BK, et al: Reduced N-acetylaspartate in prefrontal cortex of adult rats with neonatal hippocampal damage. Cereb Cortex 12:983–990, 2002
[PubMed]
 
Bilder RM, Goldman RS, Volavka J, et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018–1028, 2002
[PubMed]
 
Birchwood M: Early intervention in schizophrenia: theoretical background and clinical strategies. Br J Clin Psychol 31(pt 3): 257–278, 1992
 
Birchwood M, Iqbal Z, Chadwick P, et al: Cognitive approach to depression and suicidal thinking in psychosis, I: ontogeny of post-psychotic depression. Br J Psychiatry 177:516–521, 2000
[PubMed]
 
Black DW, Warrack G, Winokur G: The Iowa record-linkage study, I: suicides and accidental deaths among psychiatric patients. Arch Gen Psychiatry 42:71–75, 1985
[PubMed]
 
Blank MB, Mandell DS, Aiken L, et al: Co-occurrence of HIV and serious mental illness among Medicaid recipients. Psychiatr Serv 53:868–873, 2002
[PubMed]
 
Bond GR: Supported employment: evidence for an evidence-based practice. Psychiatr Rehabil J 27:345–359, 2004
[PubMed]
 
Bondolfi G, Dufour H, Patris M, et al: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155:499–504, 1998
[PubMed]
 
Borgwardt SJ, McGuire PK, Aston J, et al: Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl 51:s69–s75, 2007
 
Bourgeois M, Swendsen J, Young F, et al: Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry 161:1494–1496, 2004
[PubMed]
 
Braff DL: Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 19:233–259, 1993
[PubMed]
 
Braff DL: Psychophysiological and information processing approaches to schizophrenia, in Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York, Oxford University Press, 1999, pp 258–271
 
Braff DL, Grillon C, Geyer MA: Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206–215, 1992
[PubMed]
 
Breier A, Schreiber JL, Dyer J, et al: National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 48:239–246, 1991
[PubMed]
 
Breier AF, Malhotra AK, Su TP, et al: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294–298, 1999
[PubMed]
 
Brenner HD, Hodel B, Roder V, et al: Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia. Schizophr Bull 18:21–26, 1992
[PubMed]
 
Brown AS, Susser ES, Butler PD, et al: Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. J Nerv Ment Dis 184:71–85, 1996
[PubMed]
 
Brown ES, Nejtek VA, Perantie DC, et al: Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 23:384–388, 2003
[PubMed]
 
Brown ES, Jeffress J, Liggin JD, et al: Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66:756–760, 2005
[PubMed]
 
Brown GW, Rutter M: The measurement of family activities and relationships: a methodological study. Human Relations 19:241–263, 1966
 
Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 177:212–217, 2000
[PubMed]
 
Browne S, Clarke M, Gervin M, et al: Determinants of neurological dysfunction in first episode schizophrenia. Psychol Med 30:1433–1441, 2000
[PubMed]
 
Brunette MF, Mueser KT, Drake RE: A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev 23:471–481, 2004
[PubMed]
 
Brunette MF, Drake RE, Xie H, et al: Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 32:637–643, 2006
[PubMed]
 
Buchanan RW, Strauss ME, Kirkpatrick B, et al: Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry 51:804–811, 1994
[PubMed]
 
Buchanan RW, Strauss ME, Breier A, et al: Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry 154:363–370, 1997
[PubMed]
 
Buchanan RW, Ball MP, Weiner E, et al: Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry 162:124–129, 2005
[PubMed]
 
Buckley P, McCarthy M, Chapman P, et al: Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophr Res 36:272, 1999
 
Buka SL, Tsuang MT, Torrey EF, et al: Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 58:1032–1037, 2001
[PubMed]
 
Bustillo J, Lauriello J, Horan W, et al: The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 158:163–175, 2001
[PubMed]
 
Byerly M, Goodman W, Acholonu W, et al: Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res 76:309–316, 2005
[PubMed]
 
Cadenhead KS, Swerdlow NR, Shafer KM, et al: Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 157:1660–1668, 2000
[PubMed]
 
Cannon TD: On the nature and mechanisms of obstetric influences in schizophrenia: a review and synthesis of epidemiologic studies. Int Rev Psychiatry 9:387–397, 1997
 
Cannon TD, Rosso IM, Hollister JM, et al: A prospective cohort study of genetic and perinatal influences in the etiology of schizophrenia. Schizophr Bull 26:351–366, 2000
[PubMed]
 
Cannon TD, Cornblatt B, McGorry P: The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull 33:661–664, 2007
[PubMed]
 
Canuso CM, Hanau M, Jhamb KK, et al: Olanzapine use in women with antipsychotic-induced hyperprolactinemia. Am J Psychiatry 155:1458, 1998
[PubMed]
 
Canuso CM, Goldstein JM, Wojcik J, et al: Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111:11–20, 2002
[PubMed]
 
Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am 77:185–202, 1993
[PubMed]
 
Carpenter WT Jr, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578–583, 1988
[PubMed]
 
Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al: Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147:1138–1148, 1990
[PubMed]
 
Carpenter WT Jr: New views on the course and treatment of schizophrenia. J Psychiatr Res 32:191–195, 1998
[PubMed]
 
Carpenter WT Jr, Gold JM: Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51:969–971, 2002
[PubMed]
 
Carter CS, Perlstein W, Ganguli R, et al: Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 155:1285–1287, 1998
[PubMed]
 
Casey DE: Rabbit syndrome, in Movement Disorders in Neurology and Neuropsychiatry. Edited by Joseph AB, Young RR. Malden, MA, Blackwell Science, 1999, pp 119–122
 
Cassano GB, Pini S, Saettoni M, et al: Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry 59:60–68, 1998
[PubMed]
 
Cassens G, Inglis AK, Appelbaum PS, et al: Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16:477–499, 1990
[PubMed]
 
Censits DM, Ragland JD, Gur RC, et al: Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res 24:289–298, 1997
[PubMed]
 
Chadwick PDJ, Lowe CF, Horne PJ, et al: Modifying delusions: the role of empirical testing: innovations in cognitive-behavioral approaches to schizophrenia. Behav Ther 25:35–49, 1994
 
Chambers RA, Krystal JH, Self DW: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50:71–83, 2001
[PubMed]
 
Chang HH, Berman I: Treatment issues for patients with schizophrenia who have obsessive-compulsive symptoms. Psychiatric Annals 29:529–532, 1999
 
Cohen ST, Rulf D, Pies R: Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients. J Clin Psychiatry 66:135–136, 2005
[PubMed]
 
Coldwell CM, Bender WS: The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. Am J Psychiatry 164:393–399, 2007
[PubMed]
 
Combs DR, Adams SD, Penn DL, et al: Social Cognition and Interaction Training (SCIT) for inpatients with schizophrenia spectrum disorders: preliminary findings. Schizophr Res 91:112–116, 2007
[PubMed]
 
Conley RR, Kelly DL: Current status of antipsychotic treatment. Curr Drug Targets CNS Neurol Disord 1:123–128, 2002
[PubMed]
 
Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425, 2004
[PubMed]
 
Costa AM, de Lima MS, Faria M, et al: A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol 21:165–170, 2007
[PubMed]
 
Costa E, Grayson DR, Guidotti A: Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention? Mol Interv 3:220–229, 2003
[PubMed]
 
Costa E, Dong E, Grayson DR, et al: Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv Pharmacol 54:95–117, 2006
[PubMed]
 
Cournos F, Bakalar N: AIDS and People With Severe Mental Illness: A Handbook for Mental Health Professionals. New Haven, CT, Yale University Press, 1996
 
Covey L, Hughes DC, Glassman AH, et al: Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control 3:222–227, 1994
 
Coyle JT: The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241–253, 1996
[PubMed]
 
Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull 11:471–486, 1985
[PubMed]
 
Crow TJ, MacMillan JF, Johnson AL, et al: A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127, 1986
[PubMed]
 
Crumlish N, Whitty P, Kamali M, et al: Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr Scand 112:449–455, 2005
[PubMed]
 
Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16–22, 2002
[PubMed]
 
D'Souza DC, Abi-Saab WM, Madonick S, et al: Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608, 2005
[PubMed]
 
Dalack GW, Healy DJ, Meador-Woodruff JH: Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155:1490–1501, 1998
[PubMed]
 
David AS, Malmberg A, Brandt L, et al: IQ and risk for schizophrenia: a population-based cohort study. Psychol Med 27:1311–1323, 1997
[PubMed]
 
Davidson M, Harvey PD, Powchik P, et al: Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 152:197–207, 1995
[PubMed]
 
DeLisi LE: Defining the course of brain structural change and plasticity in schizophrenia. Psychiatry Res 92:1–9, 1999
[PubMed]
 
DeLisi LE, Sakuma M, Tew W, et al: Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 74:129–140, 1997
[PubMed]
 
Dickerson F, Boronow JJ, Ringel N, et al: Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr Res 21:75–83, 1996
[PubMed]
 
Dickerson F, Boronow J, Stallings C, et al: Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull 33:737–740, 2007
[PubMed]
 
Dickey B, Azeni H: Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 86:973–977, 1996
[PubMed]
 
Dickson RA, Glazer WM: Neuroleptic-induced hyperprolactinemia. Schizophr Res 35 (suppl):S75–S86, 1999
 
Dilk MN, Bond GR: Meta-analytic evaluation of skills training research for individuals with severe mental illness. J Consult Clin Psychol 64:1337–1346, 1996
[PubMed]
 
Dixon L, Haas G, Weiden P, et al: Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 16:69–79, 1990
[PubMed]
 
Dixon L, Weiden P, Delahanty J, et al: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903–912, 2000
[PubMed]
 
Docherty JP, Van Kammen DP, Siris SG, et al: Stages of onset of schizophrenic psychosis. Am J Psychiatry 135:420–426, 1978
[PubMed]
 
Drake RE, Mueser KT: Alcohol-use disorder and severe mental illness. Alcohol Health Res World 20:87–93, 1996
 
Drake RE, Mueser KT: Psychosocial approaches to dual diagnosis. Schizophr Bull 26:105–118, 2000
[PubMed]
 
Drake RE, Mueser KT: Substance abuse comorbidity, in Comprehensive Care of Schizophrenia. Edited by Lieberman JA, Murray RM. London, Martin Dunitz, 2001, pp 243–254
 
Drake RE, Gates C, Whitaker A, et al: Suicide among schizophrenics: a review. Compr Psychiatry 26:90–100, 1985
[PubMed]
 
Drake RE, Gates C, Cotton PG: Suicide among schizophrenics: a comparison of attempters and completed suicides. Br J Psychiatry 149:784–787, 1986
[PubMed]
 
Drake RE, Xie H, McHugo GJ, et al: The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26:441–449, 2000
[PubMed]
 
Drake RE, Essock SM, Shaner A, et al: Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv 52:469–476, 2001
[PubMed]
 
Drebing CE, Van Ormer EA, Krebs C, et al: The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. J Appl Behav Anal 38:359–372, 2005
[PubMed]
 
Eckman TA, Wirshing WC, Marder SR, et al: Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 149:1549–1555, 1992
[PubMed]
 
Eisen JL, Beer DA, Pato MT, et al: Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 154:271–273, 1997
[PubMed]
 
Elvevag B, Goldberg TE: Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1–21, 2000
[PubMed]
 
Emsley RA, Raniwalla J, Bailey PJ, et al: A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 15:121–131, 2000
[PubMed]
 
Essock SM, Covell NH, Davis SM, et al: Effectiveness of switching antipsychotic medications. Am J Psychiatry 163:2090–2095, 2006
[PubMed]
 
Evins AE, Cather C, Deckersbach T, et al: A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25:218–225, 2005
[PubMed]
 
Fadda F, Mosca E, Colombo G, et al: Effect of spontaneous ingestion of ethanol on brain dopamine metabolism. Life Sci 44:281–287, 1989
[PubMed]
 
Falloon IR, Boyd JL, McGill CW, et al: Family management in the prevention of exacerbations of schizophrenia: a controlled study. N Engl J Med 306:1437–1440, 1982
[PubMed]
 
Faraone SV, Chen WJ, Goldstein JM, et al: Gender differences in age at onset of schizophrenia. Br J Psychiatry 164:625–629, 1994
[PubMed]
 
Faraone SV, Green AI, Seidman LJ, et al: "Schizotaxia": clinical implications and new directions for research. Schizophr Bull 27:1–18, 2001
[PubMed]
 
Fenton WS: Comorbid conditions in schizophrenia. Curr Opin Psychiatry 14:17–23, 2001
 
Fenton WS, McGlashan TH: The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 143:437–441, 1986
[PubMed]
 
Fenton WS, McGlashan TH, Victor BJ, et al: Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 154:199–204, 1997
[PubMed]
 
Fenton WS, Stover EL, Insel TR: Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology (Berl) 169:365–366, 2003
[PubMed]
 
Freedman B, Chapman LJ: Early subjective experience in schizophrenic episodes. J Abnorm Psychol 82:46–54, 1973
[PubMed]
 
Frith CD, Friston KJ, Herold S, et al: Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry 167:343–349, 1995
[PubMed]
 
Fuster JM: Prefrontal neurons in networks of executive memory. Brain Res Bull 52:331–336, 2000
[PubMed]
 
Geddes JR, Lawrie SM: Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry 167:786–793, 1995
[PubMed]
 
George T, Vessicchio J: Nicotine addiction and schizophrenia. Psychiatr Times 18:39–42, 2001
 
George TP, Sernyak MJ, Ziedonis DM, et al: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56:344–346, 1995
[PubMed]
 
George TP, Ziedonis DM, Feingold A, et al: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157:1835–1842, 2000
[PubMed]
 
George TP, Vessicchio JC, Termine A, et al: A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 52:53–61, 2002
[PubMed]
 
Ghadirian AM, Chouinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 170:463–467, 1982
[PubMed]
 
Gianfrancesco FD, Grogg AL, Mahmoud RA, et al: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920–930, 2002
[PubMed]
 
Gitlin M, Nuechterlein K, Subotnik KL, et al: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 158:1835–1842, 2001
[PubMed]
 
Glazer WM: Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 61 (suppl 4): 21–26, 2000a
 
Glazer WM: Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61 (suppl 3):16–21, 2000b
 
Glazer WM: Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61 (suppl 4): 15–20, 2000c
 
Glynn SM, Sussman S: Why patients smoke. Hosp Community Psychiatry 41:1027–1028, 1990
[PubMed]
 
Glynn SM, Marder SR, Liberman RP, et al: Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry 159:829–837, 2002
[PubMed]
 
Goeders NE, Smith JE: Reinforcing properties of cocaine in the medical prefrontal cortex: primary action on presynaptic dopaminergic terminals. Pharmacol Biochem Behav 25:191–199, 1986
[PubMed]
 
Goff DC, Tsai G, Manoach DS, et al: D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628–1630, 1996
[PubMed]
 
Goff DC, Henderson DC, Evins AE, et al: A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512–514, 1999
[PubMed]
 
Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377, 2001
[PubMed]
 
Goff DC, Sullivan LM, McEvoy JP, et al: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45–53, 2005
[PubMed]
 
Goldberg TE, Hyde TM, Kleinman JE, et al: Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr Bull 19:797–804, 1993
[PubMed]
 
Goldberg TE, Weinberger DR: Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 57 (suppl 9):62–65, 1996
 
Goldman-Rakic PS: Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A 93:13473–13480, 1996
[PubMed]
 
Goldstein G, Haas GL, Pakrashi M, et al: The cycle of schizoaffective disorder, cognitive ability, alcoholism, and suicidality. Suicide Life Threat Behav 36:35–43, 2006
[PubMed]
 
Goldstein MJ, Rodnick EH, Evans JR, et al: Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry 35:1169–1177, 1978
[PubMed]
 
Gottesman II: Schizophrenia Genesis: The Origins of Madness. New York, WH Freeman, 1991
 
Granholm E, McQuaid JR, McClure FS, et al: A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. Am J Psychiatry 162:520–529, 2005
[PubMed]
 
Grech A, Van Os J, Murray RM: Influence of cannabis on the outcome of psychosis. Schizophr Res 36:41, 1999
 
Green AI, Zimmet SV, Strous RD, et al: Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 6:287–296, 1999
[PubMed]
 
Green AI, Patel JK, Goisman RM, et al: Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 22:224–235, 2000
[PubMed]
 
Green AI, Burgess ES, Dawson R, et al: Alcohol and cannabis use in schizophrenia: effects of clozapine vs risperidone. Schizophr Res 60:81–85, 2003
[PubMed]
 
Green AI, Tohen MF, Hamer RM, et al: First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 66:125–135, 2004
[PubMed]
 
Green AI, Drake RE, Brunette MF, et al: Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 164:402–408, 2007
[PubMed]
 
Green AI, Noordsy DL, Brunette MF, et al: Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 34:61–71, 2008
[PubMed]
 
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330, 1996
[PubMed]
 
Green MF: Recent studies on the neurocognitive effects of second-generation antipsychotic medications. Curr Opin Psychiatry 15:25–29, 2002
 
Green MF, Nuechterlein KH: Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 25:309–319, 1999
[PubMed]
 
Green MF, Kern RS, Braff DL, et al: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26:119–136, 2000
[PubMed]
 
Gupta S, Black DW, Arndt S, et al: Factors associated with suicide attempts among patients with schizophrenia. Psychiatr Serv 49:1353–1355, 1998
[PubMed]
 
Gur RE, Cowell P, Turetsky BI, et al: A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 55:145–152, 1998
[PubMed]
 
Haas GL, Garratt LS, Sweeney JA: Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 32:151–159, 1998
[PubMed]
 
Hafner H, Riecher-Rossler A, Maurer K, et al: First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 242:109–118, 1992
[PubMed]
 
Hafner H, Maurer K, Loffler W, et al: The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80–86, 1993
[PubMed]
 
Hafner H, Maurer K, Loffler W, et al: The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. Br J Psychiatry Suppl (23):29–38, 1994
 
Hafner H, Loffler W, Maurer K, et al: Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 100:105–118, 1999
[PubMed]
 
Hafner H, Maurer K, Trendler G, et al: The early course of schizophrenia and depression. Eur Arch Psychiatry Clin Neurosci 255:167–173, 2005
[PubMed]
 
Hambrecht M, Maurer K, Hafner H, et al: Transnational stability of gender differences in schizophrenia? An analysis based on the WHO study on determinants of outcome of severe mental disorders. Eur Arch Psychiatry Clin Neurosci 242:6–12, 1992
[PubMed]
 
Hamoui N, Kingsbury S, Anthone GJ, et al: Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg 14:349–352, 2004
[PubMed]
 
Harding CM, Brooks GW, Ashikaga T, et al: The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 144:727–735, 1987
[PubMed]
 
Harkavy-Friedman JM, Nelson E: Management of the suicidal patient with schizophrenia. Psychiatr Clin North Am 20:625–640, 1997
[PubMed]
 
Harkavy-Friedman JM, Nelson EA, Venarde DF, et al: Suicidal behavior in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life Threat Behav 34:66–76, 2004
[PubMed]
 
Harrison G: Trajectories of psychosis: towards a new social biology of schizophrenia. Epidemiol Psichiatr Soc 13:152–157, 2004
[PubMed]
 
Harrison PJ, Owen MJ: Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417–419, 2003
[PubMed]
 
Harvey PD, Keefe RE: Cognition and the new antipsychotics. Journal of Advanced Schizophrenia Brain Research 1:2–8, 1998
 
Harvey PD, Keefe RS: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176–184, 2001
[PubMed]
 
Harvey PD, Howanitz E, Parrella M, et al: Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155:1080–1086, 1998
[PubMed]
 
Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 155:1113–1116, 1998
[PubMed]
 
Hawton K, Sutton L, Haw C, et al: Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187:9–20, 2005
[PubMed]
 
Heckers S, Rauch SL, Goff D, et al: Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1:318–323, 1998
[PubMed]
 
Heila H, Isometsa ET, Henriksson MM, et al: Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 154:1235–1242, 1997
[PubMed]
 
Heila H, Isometsa ET, Henriksson MM, et al: Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry 60:200–208, 1999
[PubMed]
 
Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975–981, 2000
[PubMed]
 
Hennekens CH, Hennekens AR, Hollar D, et al: Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150:1115–1121, 2005
[PubMed]
 
Heresco-Levy U, Javitt DC, Ermilov M, et al: Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617, 1996a
 
Heresco-Levy U, Silipo G, Javitt DC: Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 32:731–740, 1996b
 
Herz MI, Glazer WM, Mostert MA, et al: Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 48:333–339, 1991
[PubMed]
 
Hinze-Selch D, Daubener W, Eggert L, et al: A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull 33:782–788, 2007
[PubMed]
 
Ho BC, Andreasen NC, Flaum M, et al: Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 157:808–815, 2000
[PubMed]
 
Hodel B, Brenner HD: Cognitive therapy with schizophrenic patients: conceptual basis, present state, future directions. Acta Psychiatr Scand Suppl 384:108–115, 1994
[PubMed]
 
Hogarty GE, Anderson CM, Reiss DJ, et al: Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, I: one-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry 43:633–642, 1986
[PubMed]
 
Hogarty GE, McEvoy JP, Ulrich RF, et al: Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 52:29, 1995
[PubMed]
 
Hogarty GE, Greenwald D, Ulrich RF, et al: Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Am J Psychiatry 154:1514–1524, 1997a
 
Hogarty GE, Kornblith SJ, Greenwald D, et al: Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Am J Psychiatry 154:1504–1513, 1997b
 
Hogarty GE, Flesher S, Ulrich R, et al: Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 61:866–876, 2004
[PubMed]
 
Hogarty GE, Greenwald DP, Eack SM: Durability and mechanism of effects of cognitive enhancement therapy. Psychiatr Serv 57:1751–1757, 2006
[PubMed]
 
Huber G, Gross G, Schuttler R, et al: Longitudinal studies of schizophrenic patients. Schizophr Bull 6:592–605, 1980
[PubMed]
 
Huber TJ, Borsutzky M, Schneider U, et al: Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr Scand 109:269–274, 2004
[PubMed]
 
Huckans MS, Blackwell AD, Harms TA, et al: Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr Serv 57:403–406, 2006
[PubMed]
 
Hummer M, Malik P, Gasser RW, et al: Osteoporosis in patients with schizophrenia. Am J Psychiatry 162:162–167, 2005
[PubMed]
 
Hunt IM, Kapur N, Windfuhr K, et al: Suicide in schizophrenia: findings from a national clinical survey. J Psychiatr Pract 12:139–147, 2006
[PubMed]
 
Hurlburt MS, Hough RL, Wood PA: Effects of substance abuse on housing stability of homeless mentally ill persons in supported housing. Psychiatr Serv 47:731–736, 1996a
 
Hurlburt MS, Wood PA, Hough RL: Providing independent housing for the homeless mentally ill: a novel approach to evaluating long-term longitudinal housing patterns. Journal of Community Psychology 24:291–310, 1996b
 
Huttenlocher PR: Neural Plasticity: The Effects of Environment on the Development of the Cerebral Cortex. Cambridge, MA, Harvard University Press, 2002
 
Hwang MY, Morgan JE, Losconzcy MF: Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci 12:91–94, 2000
[PubMed]
 
Hyman SE, Fenton WS: Medicine. What are the right targets for psychopharmacology? Science 299:350–351, 2003
[PubMed]
 
Ingvar DH, Franzen G: Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 50:425–462, 1974
[PubMed]
 
Iqbal Z, Birchwood M, Chadwick P, et al: Cognitive approach to depression and suicidal thinking in psychosis, II: testing the validity of a social ranking model. Br J Psychiatry 177:522–528, 2000
[PubMed]
 
Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689, 2001
[PubMed]
 
Jablensky A, Sartorius N, Ernberg G, et al: Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 20:1–97, 1992
[PubMed]
 
Javitt DC: Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19:151–157, 2006
[PubMed]
 
Javitt DC, Coyle JT: Decoding schizophrenia. Sci Am 290:48–55, 2004
[PubMed]
 
Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308, 1991
[PubMed]
 
Javitt DC, Silipo G, Cienfuegos A, et al: Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4:385–391, 2001
[PubMed]
 
Jeste DV: Tardive dyskinesia in older patients. J Clin Psychiatry 61 (suppl 4):27–32, 2000
 
Jeste DV, Lacro JP, Bailey A: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Presented at the 21st Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Glasgow, Scotland, July 12–16, 1998
 
Jin H, Meyer JM, Jeste DV: Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 71:195–212, 2004
[PubMed]
 
Johnson DA: Antipsychotic medication: clinical guidelines for maintenance therapy. J Clin Psychiatry 46:6–15, 1985
[PubMed]
 
Johnstone EC, Crow TJ, Johnson AL, et al: The Northwick Park Study of first episodes of schizophrenia, I: presentation of the illness and problems relating to admission. Br J Psychiatry 148:115–120, 1986
[PubMed]
 
Jolley AG, Hirsch SR, Morrison E, et al: Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 301:837–842, 1990
[PubMed]
 
Jones C, Cormac I, Silveira da Mota Neto JI, et al: Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev (4):CD000524, 2004
 
Jones PB, Barnes TR, Davies L, et al: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087, 2006
[PubMed]
 
Kampman O, Lehtinen K: Compliance in psychoses. Acta Psychiatr Scand 100:167–175, 1999
[PubMed]
 
Kane JM: Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 65 (suppl 9): 16–20, 2004
 
Kane JM, Rifkin A, Quitkin F, et al: Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 39:70–73, 1982
[PubMed]
 
Kane JM, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796, 1988
[PubMed]
 
Kane JM, Woerner MG, Pollack S, et al: Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54:327–330, 1993
[PubMed]
 
Kane JM, Handan G, Malhotra AK: Clozapine, in Current Issues in the Psychopharmacology of Schizophrenia. Edited by Breier A, Tran PV, Herrea JM, et al. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 209–223
 
Kane JM, Khanna S, Rajadhyaksha S, et al: Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 21:21–28, 2006
[PubMed]
 
Kane JM, Meltzer HY, Carson WH Jr, et al: Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 68:213–223, 2007
[PubMed]
 
Kaplan KJ, Harrow M: Positive and negative symptoms as risk factors for later suicidal activity in schizophrenics versus depressives. Suicide Life Threat Behav 26:105–121, 1996
[PubMed]
 
Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466–476, 1996
[PubMed]
 
Kapur S, Remington G: Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873–883, 2001
[PubMed]
 
Kasai K, Shenton ME, Salisbury DF, et al: Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 60:766–775, 2003a
 
Kasai K, Shenton ME, Salisbury DF, et al: Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 160:156–164, 2003b
 
Keck PE Jr, McElroy SL, Strakowski SM, et al: Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 61 (suppl 4):33–38, 2000
 
Keefe RS, Bilder RM, Davis SM, et al: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647, 2007
[PubMed]
 
Kelly DL, Shim JC, Feldman SM, et al: Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. J Psychiatr Res 38:531–536, 2004
[PubMed]
 
Kendler KS: Overview: a current perspective on twin studies of schizophrenia. Am J Psychiatry 140:1413–1425, 1983
[PubMed]
 
Kety SS, Rosenthal D, Wender PH: The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics. J Psychiatr Res 1:345–362, 1964
 
Kety SS, Wender PH, Jacobsen B, et al: Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry 51:442–455, 1994
[PubMed]
 
Khantzian EJ: The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142:1259–1264, 1985
[PubMed]
 
Kim CH, Jayathilake K, Meltzer HY: Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res 60:71–80, 2003
[PubMed]
 
Kingsbury SJ, Fayek M, Trufasiu D, et al: The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62:347–349, 2001
[PubMed]
 
Kinon BJ: The routine use of atypical antipsychotic agents: maintenance treatment. J Clin Psychiatry 59 (suppl 19):18–22, 1998
 
Kinon BJ, Ahl J, Liu-Seifert H, et al: Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577–588, 2006
[PubMed]
 
Kirli S, Caliskan M: A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 33:103–111, 1998
[PubMed]
 
Kissling WJ, Kane JM, Barnes TRE, et al: Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view, in Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Edited by Kissling WJ. Berlin, Germany, Springer-Verlag, 1991, pp 155–163
 
Kleinberg DL, Davis JM, de Coster R, et al: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57–61, 1999
[PubMed]
 
Knott V, McIntosh J, Millar A, et al: Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. Pharmacol Biochem Behav 85:228–242, 2006
[PubMed]
 
Kofoed L, Kania J, Walsh T, et al: Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 143:867–872, 1986
[PubMed]
 
Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841–852, 2002
[PubMed]
 
Koller E, Schneider B, Bennett K, et al: Clozapine-associated diabetes. Am J Med 111:716–723, 2001
[PubMed]
 
Koller EA, Cross JT, Doraiswamy PM, et al: Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23:735–744, 2003
[PubMed]
 
Kopala L, Honer WG: Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 151:1714–1715, 1994
[PubMed]
 
Kopelowicz A, Liberman RP, Zarate R: Recent advances in social skills training for schizophrenia. Schizophr Bull 32 (suppl 1): S12–S23, 2006
 
Koppel BS: Neuroleptic malignant syndrome, in Principles and Practices of Emergency Medicine, 4th Edition. Edited by Schwartz GR, Hanke BK, Mayer TA. Baltimore, MD, Williams & Wilkins, 1998, pp 1155–1605
 
Koreen AR, Siris SG, Chakos M, et al: Depression in first-episode schizophrenia. Am J Psychiatry 150:1643–1648, 1993
[PubMed]
 
Kraepelin E: Dementia Praecox and Paraphrenia (1919). New York, Robert E Krieger, 1971
 
Kramer M, Simpson G, Maciulis V, et al: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27:6–14, 2007
[PubMed]
 
Krystal JH, Karper LP, Seibyl JP, et al: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214, 1994
[PubMed]
 
Kuo CJ, Tsai SY, Lo CH, et al: Risk factors for completed suicide in schizophrenia. J Clin Psychiatry 66:579–585, 2005
[PubMed]
 
Lane A, Kinsella A, Murphy P, et al: The anthropometric assessment of dysmorphic features in schizophrenia as an index of its developmental origins. Psychol Med 27:1155–1164, 1997
[PubMed]
 
Lauriello J, Bustillo J, Keith SJ: A critical review of research on psychosocial treatment of schizophrenia. Biol Psychiatry 46:1409–1417, 1999
[PubMed]
 
Lawrie SM, Byrne M, Miller P, et al: Neurodevelopmental indices and the development of psychotic symptoms in subjects at high risk of schizophrenia. Br J Psychiatry 178:524–530, 2001
[PubMed]
 
Lee ML, Dickson RA, Campbell M, et al: Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 43:855–856, 1998
[PubMed]
 
Lehman AF: Vocational rehabilitation in schizophrenia. Schizophr Bull 21:645–656, 1995
[PubMed]
 
Lehmann HE, Hanrahan GE: Chlorpromazine: new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry 71:227–237, 1954
[PubMed]
 
Leucht S, Barnes TR, Kissling W, et al: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222, 2003a
 
Leucht S, Wahlbeck K, Hamann J, et al: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589, 2003b
 
Leucht S: Amisulpride: a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 7 (suppl 1): S15–S20, 2004
 
Levinson DF, Umapathy C, Musthaq M: Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 156:1138–1148, 1999
[PubMed]
 
Lewis DA, Gonzalez-Burgos G: Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12:1016–1022, 2006
[PubMed]
 
Lewis DA, Levitt P: Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409–432, 2002
[PubMed]
 
Lewis DA, Lieberman JA: Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325–334, 2000
[PubMed]
 
Lewis DA, Hashimoto T, Volk DW: Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312–324, 2005
[PubMed]
 
Lewis SW, Davies L, Jones PB, et al: Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 10:iii–iv, ix–xi, 1–165, 2006
 
Liberman RP, Wallace CJ, Blackwell G, et al: Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. Am J Psychiatry 155:1087–1091, 1998
[PubMed]
 
Liddle PF, Barnes TR, Morris D, et al: Three syndromes in chronic schizophrenia. Br J Psychiatry Suppl (7):119–122, 1989
 
Lieberman JA: Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46:729–739, 1999
[PubMed]
 
Lieberman JA: Neurobiology and the natural history of schizophrenia. J Clin Psychiatry 67:e14, 2006
 
Lieberman JA, Saltz BL, Johns CA, et al: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510, 1991
[PubMed]
 
Lieberman JA, Jody D, Geisler S, et al: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369–376, 1993
[PubMed]
 
Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223, 2005
[PubMed]
 
Littrell KH, Petty RG, Hilligoss NM, et al: Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 21:217–221, 2001
[PubMed]
 
Loebel AD, Lieberman JA, Alvir JM, et al: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183–1188, 1992
[PubMed]
 
Loh C, Meyer JM, Leckband SG: A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 18:23–31, 2006
[PubMed]
 
Lysaker P, Bell M, Beam-Goulet J, et al: Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 182:109–112, 1994
[PubMed]
 
Macleod J, Davey Smith G, Hickman M: Does cannabis use cause schizophrenia? Lancet 367:1055, 2006
[PubMed]
 
Mandel MR, Severe JB, Schooler NR, et al: Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Arch Gen Psychiatry 39:197–203, 1982
[PubMed]
 
Manoach DS, Press DZ, Thangaraj V, et al: Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry 45:1128–1137, 1999
[PubMed]
 
Marder SR: Integrating pharmacological and psychosocial treatments for schizophrenia. Acta Psychiatr Scand Suppl (407): 87–90, 2000
 
Marder SR: Drug initiatives to improve cognitive function. J Clin Psychiatry 67 (suppl 9):31–35; discussion 36–42, 2006
 
Marder SR, Wirshing WC, Mintz J, et al: Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 153:1585–1592, 1996
[PubMed]
 
Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538–546, 1997
[PubMed]
 
Marder SR, Essock SM, Miller AL, et al: The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28:5–16, 2002
[PubMed]
 
Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349, 2004
[PubMed]
 
Margolese HC, Chouinard G, Kolivakis TT, et al: Tardive dyskinesia in the era of typical and atypical antipsychotics, part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 50:703–714, 2005
[PubMed]
 
Martin LF, Leonard S, Hall MH, et al: Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 144:611–614, 2007
 
May PR, Tuma AH, Dixon WJ: For better or worse? Outcome variance with psychotherapy and other treatments for schizophrenia. J Nerv Ment Dis 165:231–239, 1978
 
McEvoy JP, Freudenreich O, Levin ED, et al: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 119:124–126, 1995a
 
McEvoy J, Freudenreich O, McGee M, et al: Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 37:550–552, 1995b
 
McEvoy JP, Meyer JM, Goff DC, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32, 2005
[PubMed]
 
McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610, 2006
[PubMed]
 
McGlashan TH: The profiles of clinical deterioration in schizophrenia. J Psychiatr Res 32:133–141, 1998
[PubMed]
 
McGlashan TH: Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 46:899–907, 1999
[PubMed]
 
McGlashan TH, Carpenter WT Jr: Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 33:231–239, 1976
[PubMed]
 
McGlashan TH, Addington J, Cannon T, et al: Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophr Bull 33:715–726, 2007
[PubMed]
 
McGorry PD, McFarlane C, Patton GC, et al: The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand 92:241–249, 1995
[PubMed]
 
McGorry PD, Yung AR, Phillips LJ, et al: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928, 2002
[PubMed]
 
McGurk SR, Mueser KT, Feldman K, et al: Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. Am J Psychiatry 164:437–441, 2007
[PubMed]
 
Mednick SA, Machon RA, Huttunen MO, et al: Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45:189–192, 1988
[PubMed]
 
Meehl PE: Schizotaxia, schizotypy, schizophrenia. Am Psychol 17:827–838, 1962
 
Meehl PE: Schizotaxia revisited. Arch Gen Psychiatry 46:935–944, 1989
[PubMed]
 
Melle I, Johannesen JO, Friis S, et al: Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 163:800–804, 2006
[PubMed]
 
Meltzer HY: Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 40:59–68, 1985
[PubMed]
 
Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 99 (suppl):S18–S27, 1989
 
Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82–91, 2003
[PubMed]
 
Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17, 2004
[PubMed]
 
Meyer J, Nasrallah H: Medical Illness and Schizophrenia. American Psychiatric Publishing, 2003
 
Miller DD, McEvoy JP, Davis SM, et al: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80:33–43, 2005
[PubMed]
 
Minkoff K: An integrated treatment model for dual diagnosis of psychosis and addiction. Hosp Community Psychiatry 40:1031–1036, 1989
[PubMed]
 
Moghaddam B: Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174:39–44, 2004
[PubMed]
 
Moghaddam B, Jackson M: Effect of stress on prefrontal cortex function. Neurotox Res 6:73–78, 2004
[PubMed]
 
Montero I, Hernandez I, Asencio A, et al: Do all people with schizophrenia receive the same benefit from different family intervention programs? Psychiatry Res 133:187–195, 2005
[PubMed]
 
Montross LP, Zisook S, Kasckow J: Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry 17:173–182, 2005
[PubMed]
 
Morrison D, Clark D, Goldfarb E, et al: Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry 155:855, 1998
[PubMed]
 
Mortensen PB, Norgaard-Pedersen B, Waltoft BL, et al: Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull 33:741–744, 2007
[PubMed]
 
Mueser KT, Bennett M, Kushner MG: Epidemiology of substance use disorders among persons with chronic mental illnesses, in Double Jeopardy: Chronic Mental Illness and Substance Abuse. Edited by Lehman AF, Dixon L. New York, Harwood Academic Publishers, 1995, pp 9–25
 
Mueser KT, Bond GR, Drake RE, et al: Models of community care for severe mental illness: a review of research on case management. Schizophr Bull 24:37–74, 1998
[PubMed]
 
Mueser KT, Noordsy DL, Fox L, et al: Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 12:242–252, 2003
[PubMed]
 
Mueser KT, Meyer PS, Penn DL, et al: The Illness Management and Recovery program: rationale, development, and preliminary findings. Schizophr Bull 32 (suppl 1):S32–S43, 2006
 
Mukherjee S, Decina P, Bocola V, et al: Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68–73, 1996
[PubMed]
 
Muller P, Bandelow B, Gaebel W, et al: Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification. Br J Psychiatry Suppl (18):140–144, 1992
 
Murray RM: Neurodevelopmental schizophrenia: the rediscovery of dementia praecox. Br J Psychiatry Suppl (25):6–12, 1994
 
Negrete JC, Knapp WP, Douglas DE, et al: Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 16:515–520, 1986
[PubMed]
 
Nelson HE, Pantelis C, Carruthers K, et al: Cognitive functioning and symptomatology in chronic schizophrenia. Psychol Med 20:357–365, 1990
[PubMed]
 
Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118, 1999
[PubMed]
 
Noordsy DL, O'Keefe C, Mueser KT, et al: Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 52:501–507, 2001
[PubMed]
 
Nuechterlein KH, Dawson ME: Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 10:160–203, 1984
[PubMed]
 
O'Donnell P, Lewis BL, Weinberger DR, et al: Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex 12:975–982, 2002
[PubMed]
 
O'Keane V, Meaney AM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25:26–31, 2005
[PubMed]
 
Ohlsen RI, Pilowsky LS: The place of partial agonism in psychiatry: recent developments. J Psychopharmacol 19:408–413, 2005
[PubMed]
 
Olney JW, Farber NB: Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998–1007, 1995
[PubMed]
 
Ongur D, Goff DC: Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 75:349–362, 2005
[PubMed]
 
Osher FC, Kofoed LL: Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry 40:1025–1030, 1989
[PubMed]
 
Osher FC, Goldberg RW, McNary SW, et al: Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv 54:842–847, 2003
[PubMed]
 
Osser DN: Neuroleptic-induced pseudoparkinsonism, in Movement Disorders in Neurology and Neuropsychiatry. Edited by Joseph AB, Young RR. Malden, MA, Blackwell Science, 1999, pp 61–68
 
Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767–770, 1999
[PubMed]
 
Pantelis C, Velakoulis D, McGorry PD, et al: Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281–288, 2003
[PubMed]
 
Park S, Holzman PS: Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 49:975–982, 1992
[PubMed]
 
Park S, Holzman PS, Goldman-Rakic PS: Spatial working memory deficits in the relatives of schizophrenic patients. Arch Gen Psychiatry 52:821–828, 1995
[PubMed]
 
Patil ST, Zhang L, Martenyi F, et al: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102–1107, 2007
[PubMed]
 
Penn DL, Mueser KT: Research update on the psychosocial treatment of schizophrenia. Am J Psychiatry 153:607–617, 1996
[PubMed]
 
Penn DL, Addington J, Pinkham A: Social cognitive impairments, in Textbook of Schizophrenia. Edited by Lieberman JA, Stroup TS, Perkins DO. Washington, DC, American Psychiatric Publishing, 2006, pp 261–274
 
Perala J, Suvisaari J, Saarni SI, et al: Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19–28, 2007
[PubMed]
 
Petrakis IL, O'Malley S, Rounsaville B, et al: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 172:291–297, 2004
[PubMed]
 
Petrakis IL, Poling J, Levinson C, et al: Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 57:1128–1137, 2005
[PubMed]
 
Petrakis IL, Leslie D, Finney JW, et al: Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 15:44–49, 2006
[PubMed]
 
Pfohl B, Winokur G: The evolution of symptoms in institutionalized hebephrenic/catatonic schizophrenics. Br J Psychiatry 141:567–572, 1982
[PubMed]
 
Phillips SD, Burns BJ, Edgar ER, et al: Moving assertive community treatment into standard practice. Psychiatr Serv 52:771–779, 2001
[PubMed]
 
Pietzcker A, Gaebel W, Kopcke W: Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2 year results of German multicenter study. J Psychiatr Res 27:321–339, 1993
 
Pilling S, Bebbington P, Kuipers E, et al: Psychological treatments in schizophrenia, II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 32:783–791, 2002
[PubMed]
 
Pilowsky LS, Kerwin RW, Murray RM: Schizophrenia: a neurodevelopmental perspective. Neuropsychopharmacology 9:83–91, 1993
[PubMed]
 
Pitschel-Walz G, Leucht S, Bauml J, et al: The effect of family interventions on relapse and rehospitalization in schizophrenia—a meta-analysis. Schizophr Bull 27:73–92, 2001
[PubMed]
 
Porteous DJ, Thomson P, Brandon NJ, et al: The genetics and biology of DISC1—an emerging role in psychosis and cognition. Biol Psychiatry 60:123–131, 2006
[PubMed]
 
Potkin SG, Jin Y, Bunney BG, et al: Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145–147, 1999
[PubMed]
 
Potkin SG, Alphs L, Hsu C, et al: Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 54:444–452, 2003
[PubMed]
 
Potvin S, Stip E, Lipp O, et al: Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 22:1277–1285, 2006
[PubMed]
 
Poyurovsky M, Dorfman-Etrog P, Hermesh H, et al: Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. Int Clin Psychopharmacol 15:169–173, 2000
[PubMed]
 
Qin P, Nordentoft M: Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch Gen Psychiatry 62:427–432, 2005
[PubMed]
 
Radomsky ED, Haas GL, Mann JJ, et al: Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am J Psychiatry 156:1590–1595, 1999
[PubMed]
 
Ran MS, Xiang MZ, Mao WJ, et al: Characteristics of suicide attempters and nonattempters with schizophrenia in a rural community. Suicide Life Threat Behav 35:694–701, 2005
[PubMed]
 
Rapp CA, Goscha RJ: The principles of effective case management of mental health services. Psychiatr Rehabil J 27:319–333, 2004
[PubMed]
 
Regier DA, Farmer ME, Rae DS, et al: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511–2518, 1990
[PubMed]
 
Remington G, Kapur S: Neuroleptic-induced extrapyramidal symptoms and the role of combined serotonin/dopamine antagonist. J Clin Psychiatry 14:14–24, 1996
 
Remington G, Kapur S, Zipursky R: APA Practice guideline for schizophrenia: risperidone equivalents. American Psychiatric Association. Am J Psychiatry 155:1301–1302, 1998
[PubMed]
 
Riecher-Rossler A, Hafner H, Stumbaum M, et al: Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20:203–214, 1994
[PubMed]
 
Ries RK, Dyck DG, Short R, et al: Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatr Serv 55:445–447, 2004
[PubMed]
 
Ripoll N, Bronnec M, Bourin M: Nicotinic receptors and schizophrenia. Curr Med Res Opin 20:1057–1074, 2004
[PubMed]
 
Robinson DG, Woerner MG, Alvir JM, et al: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156:544–549, 1999
[PubMed]
 
Rog DJ: The evidence on supported housing. Psychiatr Rehabil J 27:334–344, 2004
[PubMed]
 
Rolfe TJ, McGory P, Cooks J, et al: Cannabis use in first episode psychosis: incidence and short-term outcome. Schizophr Res 36:313, 1999
 
Rosenberg SD, Goodman LA, Osher FC, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 91:31–37, 2001
[PubMed]
 
Rosenheck RA, Leslie DL, Sindelar J, et al: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163:2080–2089, 2006
[PubMed]
 
Ross CA, Margolis RL, Reading SA, et al: Neurobiology of schizophrenia. Neuron 52:139–153, 2006
[PubMed]
 
Rossau CD, Mortensen PB: Risk factors for suicide in patients with schizophrenia: nested case-control study. Br J Psychiatry 171:355–359, 1997
[PubMed]
 
Rosso IM, Bearden CE, Hollister JM, et al: Childhood neuromotor dysfunction in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull 26:367–378, 2000
[PubMed]
 
Roth RM, Brunette MF, Green AI: Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 7:283–291, 2005
[PubMed]
 
Roy A: Risk factors for suicide in psychiatric patients. Arch Gen Psychiatry 39:1089–1095, 1982a
 
Roy A: Suicide in chronic schizophrenia. Br J Psychiatry 141:171–177, 1982b
 
Rubio G, Martinez I, Ponce G, et al: Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51:531–539, 2006
[PubMed]
 
Russell AJ, Munro JC, Jones PB, et al: Schizophrenia and the myth of intellectual decline. Am J Psychiatry 154:635–639, 1997
[PubMed]
 
Sacco KA, Termine A, Seyal A, et al: Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62:649–659, 2005
[PubMed]
 
Salisbury DF, Kuroki N, Kasai K, et al: Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 64:521–529, 2007
[PubMed]
 
Saltz BL, Woerner MG, Kane JM, et al: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266:2402–2406, 1991
[PubMed]
 
Sax KW, Strakowski SM, Keck PE Jr, et al: Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry 168:68–71, 1996
[PubMed]
 
Sayers SL, Campbell EC, Kondrich J, et al: Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 193:379–386, 2005
[PubMed]
 
Saykin AJ, Gur RC, Gur RE, et al: Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618–624, 1991
[PubMed]
 
Saykin AJ, Shtasel DL, Gur RE, et al: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51:124–131, 1994
[PubMed]
 
Schooler NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 64 (suppl 16):14–17, 2003
 
Schooler NR: Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 67 (suppl 5):19–23, 2006
 
Schooler NR, Keith SJ, Severe JB, et al: Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 54:453–463, 1997
[PubMed]
 
Schooler NR, Rabinowitz J, Davidson M, et al: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162:947–953, 2005
[PubMed]
 
Schultz SK, Miller DD, Oliver SE, et al: The life course of schizophrenia: age and symptom dimensions. Schizophr Res 23:15–23, 1997
[PubMed]
 
Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38, 2002
[PubMed]
 
Selemon LD, Goldman-Rakic PS: The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45:17–25, 1999
[PubMed]
 
Sellwood W, Barrowclough C, Tarrier N, et al: Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. Acta Psychiatr Scand 104:346–355, 2001
[PubMed]
 
Selzer JA, Lieberman JA: Schizophrenia and substance abuse. Psychiatr Clin North Am 16:401–412, 1993
[PubMed]
 
Sevy S, Kay SR, Opler LA, et al: Significance of cocaine history in schizophrenia. J Nerv Ment Dis 178:642–648, 1990
[PubMed]
 
Sewell DD: Schizophrenia and HIV. Schizophr Bull 22:465–473, 1996
[PubMed]
 
Sharma A, Sorrell JH: Aripiprazole-induced parkinsonism. Int Clin Psychopharmacol 21:127–129, 2006
[PubMed]
 
Shirzadi AA, Ghaemi SN: Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 14:152–164, 2006
[PubMed]
 
Simon AE, Cattapan-Ludewig K, Zmilacher S, et al: Cognitive functioning in the schizophrenia prodrome. Schizophr Bull 33:761–771, 2007
[PubMed]
 
Simpson GM: The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 61 (suppl 4):39–44, 2000
 
Siris SG: Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 16:111–122, 1990
[PubMed]
 
Siris SG: Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 157:1379–1389, 2000a
 
Siris SG: Management of depression in schizophrenia. Psychiatric Annals 30:13–19, 2000b
 
Siris SG, Morgan V, Fagerstrom R, et al: Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch Gen Psychiatry 44:533–539, 1987
[PubMed]
 
Siris SG, Mason SE, Bermanzohn PC, et al: Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 29:127–133, 1993
[PubMed]
 
Smelson DA, Williams J, Kaune M, et al: Reduced cue-elicited cocaine craving and relapses following treatment with risperidone. Presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, May 13–18, 2000
 
Smelson DA, Ziedonis D, Williams J, et al: The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 26:9–12, 2006
[PubMed]
 
Soni SD, Brownlee M: Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 84:272–276, 1991
[PubMed]
 
Spence SA, Hirsch SR, Brooks DJ, et al: Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of "hypofrontality" with recovery from acute schizophrenia. Br J Psychiatry 172:316–323, 1998
[PubMed]
 
Spencer T, Biederman J, Wilens T, et al: Is attention-deficit hyperactivity disorder in adults a valid disorder? Harv Rev Psychiatry 1:326–335, 1994
[PubMed]
 
Spohn HE, Strauss ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98:367–380, 1989
[PubMed]
 
Stanton JM: Weight gain associated with neuroleptic medication: a review. Schizophr Bull 21:463–472, 1995
[PubMed]
 
Stefansson H, Steinthorsdottir V, Thorgeirsson TE, et al: Neuregulin 1 and schizophrenia. Ann Med 36:62–71, 2004
[PubMed]
 
Stein LI, Test MA: Alternative to mental hospital treatment, I: conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 37:392–397, 1980
[PubMed]
 
Steinberg ML, Williams JM, Ziedonis DM: Financial implications of cigarette smoking among individuals with schizophrenia. Tob Control 13:206, 2004
[PubMed]
 
Stroup TS, Lieberman JA, McEvoy JP, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622, 2006
[PubMed]
 
Stroup TS, Lieberman JA, McEvoy JP, et al: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164:415–427, 2007
[PubMed]
 
Strous RD, Patel JK, Zimmet S, et al: Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. Am J Psychiatry 156:973–974, 1999
[PubMed]
 
Stuss DT, Benson DF: The Frontal Lobes. New York, Raven Press, 1986
 
Susman VL: Clinical management of neuroleptic malignant syndrome. Psychiatr Q 72:325–336, 2001
[PubMed]
 
Svensson TH, Mathe JM, Andersson JL, et al: Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]. J Clin Psychopharmacol 15:11S–18S, 1995
 
Szarfman A, Tonning JM, Levine JG, et al: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26:748–758, 2006
[PubMed]
 
Szymanski S, Lieberman JA, Alvir JM, et al: Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 152:698–703, 1995
[PubMed]
 
Tamminga CA: Principles of the pharmacotherapy of schizophrenia, in Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York, Oxford University Press, 1999, pp 272–290
 
Tamminga CA: Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411–420, 2002
[PubMed]
 
Tarrier N, Barrowclough C, Vaughn C, et al: The community management of schizophrenia. A controlled trial of a behavioural intervention with families to reduce relapse. Br J Psychiatry 153:532–542, 1988
[PubMed]
 
Tarrier N, Kinney C, McCarthy E, et al: Two-year follow-up of cognitive—behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia. J Consult Clin Psychol 68:917–922, 2000
[PubMed]
 
Tarsy D, Baldessarini RJ: Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21:589–598, 2006
[PubMed]
 
Tibbo P, Kroetsch M, Chue P, et al: Obsessive-compulsive disorder in schizophrenia. J Psychiatr Res 34:139–146, 2000
[PubMed]
 
Tollefson GD, Beasley CM Jr, Tamura RN, et al: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154:1248–1254, 1997
[PubMed]
 
Tollefson GD, Sanger TM, Lu Y, et al: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250–258, 1998
[PubMed]
 
Tollefson GD, Andersen SW, Tran PV: The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 46:365–373, 1999
[PubMed]
 
Tollefson GD, Birkett MA, Kiesler GM, et al: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52–63, 2001
[PubMed]
 
Toomey R, Faraone SV, Seidman LJ, et al: Association of neuropsychological vulnerability markers in relatives of schizophrenic patients. Schizophr Res 31:89–98, 1998
[PubMed]
 
Tran PV, Dellva MA, Tollefson GD, et al: Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 172:499–505, 1998
[PubMed]
 
Tsai G, Yang P, Chung LC, et al: D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081–1089, 1998
[PubMed]
 
Tsai G, Lane HY, Yang P, et al: Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452–456, 2004
[PubMed]
 
Tsai GE, Yang P, Chang YC, et al: D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230–234, 2006
[PubMed]
 
Tsankova N, Renthal W, Kumar A, et al: Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8:355–367, 2007
[PubMed]
 
Tsuang MT, Winokur G, Crowe RR: Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. Br J Psychiatry 137:497–504, 1980
[PubMed]
 
Tsuang MT, Fleming JA, Simpson JC: Suicide and schizophrenia, in The Harvard Medical School Guide to Suicide Assessment and Intervention. Edited by Jacobs DG. San Francisco, CA, Jossey-Bass, 1999a, pp 287–299
 
Tsuang MT, Stone WS, Seidman LJ, et al: Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry 45:1412–1418, 1999b
 
Tsuang MT, Stone WS, Faraone SV: Towards the prevention of schizophrenia. Biol Psychiatry 48:349–356, 2000
[PubMed]
 
van Haren NE, Pol HE, Schnack HG, et al: Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry 63:106–113, 2007
 
van Os J, Drukker M, a Campo J, et al: Validation of remission criteria for schizophrenia. Am J Psychiatry 163:2000–2002, 2006
 
Varsamis J, Adamson JD: Early schizophrenia. Can Psychiatr Assoc J 16:487–497, 1971
[PubMed]
 
Volavka J, Czobor P, Sheitman B, et al: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255–262, 2002
[PubMed]
 
Waddington JL: Schizophrenia: developmental neuroscience and pathobiology. Lancet 341:531–536, 1993
[PubMed]
 
Waddington JL, Buckley PF, Scully PJ, et al: Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? J Psychiatr Res 32:179–189, 1998
[PubMed]
 
Walker E, Lewis N, Loewy R, et al: Motor dysfunction and risk for schizophrenia. Dev Psychopathol 11:509–523, 1999
[PubMed]
 
Wang PS, Walker AM, Tsuang MT, et al: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59:1147–1154, 2002
[PubMed]
 
Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660–669, 1987
[PubMed]
 
Weinberger DR: On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 14:1S–11S, 1996
 
Weinberger DR, Berman KF, Zec RF: Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 43:114–124, 1986
[PubMed]
 
Weinberger DR, McClure RK: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry 59:553–558, 2002
[PubMed]
 
Weiner E, Ball MP, Summerfelt A, et al: Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 158:635–637, 2001
[PubMed]
 
Weiss RD, Griffin ML, Kolodziej ME, et al: A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 164:100–107, 2007
[PubMed]
 
Werneke U, Taylor D, Sanders TA: Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 17:145–160, 2002
[PubMed]
 
Westermeyer JF, Harrow M, Marengo JT: Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. J Nerv Ment Dis 179:259–266, 1991
[PubMed]
 
Wilkins JN: Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 23:215–228, 1997
[PubMed]
 
Williams GV, Castner SA: Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 139:263–276, 2006
[PubMed]
 
Williams JM, Ziedonis DM, Foulds J: A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr Serv 55:1064–1066, 2004
[PubMed]
 
Windgassen K, Wesselmann U, Schulze Monking H: Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology 33:142–146, 1996
[PubMed]
 
Wirshing DA, Spellberg BJ, Erhart SM, et al: Novel antipsychotics and new onset diabetes. Biol Psychiatry 44:778–783, 1998
[PubMed]
 
Wirshing DA, Wirshing WC, Kysar L, et al: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358–363, 1999
[PubMed]
 
Wirshing DA, Erhart SM, Pierre JM: Nonextrapyramidal side effects of novel antipsychotics. Curr Opin Psychiatry 13:45–50, 2000
 
Wirshing DA, Boyd JA, Meng LR, et al: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856–865, 2002
[PubMed]
 
Wirshing DA, Pierre JM, Erhart SM, et al: Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 26:165–190, 2003
[PubMed]
 
Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325–351, 1991
[PubMed]
 
Wyatt RJ: Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 38:1–3, 1995
[PubMed]
 
Wyatt RJ, Damiani LM, Henter ID: First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry Suppl 172:77–83, 1998
[PubMed]
 
Wykes T, Reeder C, Corner J, et al: The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 25:291–307, 1999
[PubMed]
 
Yazigi RA, Quintero CH, Salameh WA: Prolactin disorders. Fertil Steril 67:215–225, 1997
[PubMed]
 
Yung AR, McGorry PD: The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry 30:587–599, 1996a
 
Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 22:353–370, 1996b
 
Zakzanis KK: Neuropsychological correlates of positive vs. negative schizophrenic symptomatology. Schizophr Res 29:227–233, 1998
[PubMed]
 
Ziedonis D, Richardson T, Lee E, et al: Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 28:309–314, 1992
[PubMed]
 
Ziedonis D, Williams J, Corrigan P, et al: Management of substance abuse in schizophrenia. Psychiatr Ann 30:67–75, 2000
 
Ziedonis D, Williams JM, Smelson D: Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am J Med Sci 326:223–230, 2003
[PubMed]
 
Ziegenbein M, Sieberer M, Calliess IT, et al: Aripiprazole-induced extrapyramidal side effects in a patient with schizoaffective disorder. Aust N Z J Psychiatry 40:194–195, 2006
[PubMed]
 
Zimmet SV, Strous RD, Burgess ES, et al: Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 20:94–98, 2000
[PubMed]
 
Zipursky RB, Lim KO, Sullivan EV, et al: Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 49:195–205, 1992
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following is an example of a negative symptom of schizophrenia?
2.
Which of the following provides the best predictor of long-term functional outcome in patients with schizophrenia?
3.
Among the cognitive functions known to be disturbed in schizophrenia, which of the following is considered the most severe?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
Topic Collections
Psychiatric News
PubMed Articles
Paliperidone extended-release: safety and tolerability from a metabolic profile perspective. Clin Drug Investig 2013;33(12):867-76.doi:10.1007/s40261-013-0100-2.
Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry 2014;75(6):e573-7.doi:10.4088/JCP.13m08795.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation